Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Erwin A. Kruger is active.

Publication


Featured researches published by Erwin A. Kruger.


Seminars in Oncology | 2001

A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer.

William D. Figg; Phil Arlen; James L. Gulley; Patricia Fernandez; Marianne Noone; Kathy Fedenko; Michael Hamilton; Catherine Parker; Erwin A. Kruger; James M. Pluda; William L. Dahut

New therapeutic alternatives are needed to improve outcomes in patients with androgen-independent prostate cancer (AIPC). For several years, researchers at the National Cancer Institute have been interested in elucidating the importance of angiogenesis in the pathogenesis of prostate cancer and in identifying inhibitors of this process. Thalidomide has been shown to inhibit the ability of tumors to recruit new blood vessels. In a recent phase II trial of thalidomide in AIPC, 28% of patients achieved a prostate-specific antigen (PSA) decrease of >40%. The taxane docetaxel also produces PSA and measurable disease responses when used as monotherapy or as a component of combination chemotherapy for AIPC. Thus, based on the single-agent activity of thalidomide and docetaxel, we initiated a randomized phase II study of weekly docetaxel with or without thalidomide, 200 mg at bedtime, in patients with chemotherapy-naive metastatic AIPC. Docetaxel, 30 mg/m(2) intravenously, was administered every 7 days for 3 weeks, followed by a 1-week rest period. Both regimens have been well tolerated among the first 59 treated patients, with a near absence of grade (3/4) myelosuppression. Fatigue, hyperglycemia, and pulmonary toxicity were seen in both groups. Thrombotic events have been seen in the combination arm. Thirty-five percent (6 of 17) of the patients receiving docetaxel alone and 53% (19 of 36) of those receiving docetaxel and thalidomide have had a PSA decrease of at least 50%. Combining a cytotoxic agent with an angiogenesis inhibitor is a promising area of investigation for prostate cancer management.


Expert Opinion on Investigational Drugs | 2000

TNP-470: an angiogenesis inhibitor in clinical development for cancer

Erwin A. Kruger; William D. Figg

TNP-470, an analogue of fumagillin, has been shown to inhibit angiogenesis in vitro and in vivo. In 1992, TNP-470 entered clinical development for cancer as an anti-angiogenic agent. It is currently in Phase I/II trials in Kaposi’s sarcoma, renal cell carcinoma, brain cancer, breast cancer, cervical cancer and prostate cancer. In early clinical reports, TNP-470 is tolerated up to 177 mg/m2 with neurotoxic effects (fatigue, vertigo, ataxia, and loss of concentration) being the principal dose limiting toxicity (DLT). Terminal half-life values are short and have shown intermittent and intrapatient variation (range: 0.05 - 1.07 h). Recently, mechanistic studies have identified cell cycle mediators and the protein methionine aminopeptidase-2 (MetAP-2) as molecular targets of TNP-470 and fumagillin. Animal studies confirm some toxic effects on normal angiogenic processes such as the female reproductive system and wound healing, which will require caution and close monitoring in the clinic. TNP-470 is one of the first anti-angiogenic compounds to enter clinical trials, making it a valuable prototype for future trials of angiogenesis inhibitors in oncology.


Investigational New Drugs | 2002

Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer.

William D. Figg; Erwin A. Kruger; Douglas K. Price; Sonia Kim; William D. Dahut

Prostate cancer is the most frequentlydiagnosed malignancy and the second mostcommon cause of cancer-related death in menin the United States. Unfortunately, atthe current time, no curative treatmentsare available for metastatic prostatecancer. As is the case for most solidtumors, the recruitment of blood vessels(angiogenesis) is key for the progressionand metastasis of prostate cancer. Inhibition of this process is an attractiveapproach to treatment. Many antiangiogenicagents are currently in clinicaldevelopment. The following discussion willoutline the importance of angiogenesis inthe metastasis and progression of prostatecancer, summarize the current surrogatemarkers of angiogenesis available for thedrug development of antiangiogenic agents,and review examples of investigationalagents that target tumor angiogenesis(e.g., TNP-470, Thalidomide, CC5013,Carboxyamido-triazole (CAI), Endostatin,SU5416 , SU6668, Bevacizumab (Anti-VEGFrhuMAb), and 2-Methoxyestradiol).


Seminars in Oncology | 2001

Approaches to preclinical screening of antiangiogenic agents

Erwin A. Kruger; Paul H. Duray; Douglas K. Price; James M. Pluda; William D. Figg

Angiogenesis, or new blood vessel growth, is essential for the growth, invasion, and metastasis of solid tumors. The inhibition of this process, or antiangiogenesis, is a promising new therapeutic anticancer strategy. Several antiangiogenic compounds are currently in preclinical or clinical development for the treatment of cancer. However, the challenge for the discovery and characterization of antiangiogenic targets remains in developing efficient in vitro or in vivo preclinical angiogenesis screening assays to assess and compare antiangiogenic activity. Several semiquantitative or quantitative angiogenesis assays exist, including in vitro endothelial cell systems and ex vivo or in vivo neovascularization models utilizing mouse, rat, or human tissues. We describe the more common and cost-effective angiogenesis assays currently in use, summarizing their unique advantages and disadvantages. Since angiogenesis inhibition is a novel therapeutic modality towards controlling solid tumors, antiangiogenic drug development underlines the importance in describing, standardizing, and developing quantitative screening assays for the next generation of antiangiogenic agents.


Invasion & Metastasis | 1998

UCN-01, a Protein Kinase C Inhibitor, Inhibits Endothelial Cell Proliferation and Angiogenic Hypoxic Response

Erwin A. Kruger; Mikhail V. Blagosklonny; Shannon C. Dixon; William D. Figg

Angiogenesis is required for tumor formation and growth; inhibition of angiogenesis is a promising new approach in cancer therapy. UCN-01, a protein kinase C (PKC) inhibitor, induces growth arrest and apoptosis in cancer cells and was recently introduced in a phase I clinical trial. We demonstrate that UCN-01, at concentrations lower than those necessary to inhibit cancer cell growth, inhibit proliferation of human endothelial cells in vitro. Moreover, UCN-01, at concentrations as low as 32 nM, prevent microvessel outgrowth from explant cultures of rat aortic rings. Since hypoxia activates hypoxia-inducible factor (HIF-1)-dependent transcription in cancer cells that, in a paracrine fashion, drive tumor angiogenesis, we investigated the effects of UCN-01 on HIF-1-responsive promoter constructs. We report that, in addition to direct inhibitory effects on endothelial cell growth, UCN-01 abrogates hypoxia-mediated transactivation of HIF-1-responsive promoters in a prostate cancer cell line. We conclude that UCN-01, at clinically relevant concentrations, exerts an anti-neovascularization effect by blocking two important steps in vessel formation: (1) the response of cancer cells to hypoxia, and (2) endothelial cell proliferation.


Therapeutic Drug Monitoring | 2002

5'-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis

Douglas K. Price; Yuichi Ando; Erwin A. Kruger; Michael Weiss; William D. Figg

Despite its known teratogenic effects, thalidomide has been used to treat a variety of diseases ranging from alleviation of autoimmune disorders to prevention of metastasis of cancers. The exact method of action of thalidomide and its derivatives is still under investigation. Thalidomide undergoes very little metabolism by the cytochrome P450 system in vitro, but at least two hydroxylated metabolites have been found in humans. The two metabolites are 5-hydroxythalidomide, formed by hydroxylation of the phthalimide ring, possibly via arene oxides, and 5´-hydroxythalidomide, formed by hydroxylation of the glutarimide ring, leading to diastereomeric products. These two metabolites, along with another minor metabolite of thalidomide, were tested in a rat aortic ring assay, a human saphenous vein model, and a tube formation assay to assess the metabolites ability to inhibit angiogenesis. Of the metabolites tested, only 5´-OH-thalidomide showed biologic activity in the rat aortic ring assay, and none of the metabolites showed activity in the human model. The studies with thalidomide and thalidomide metabolites underline the difficulty and complexity of trying to isolate and evaluate a single biologically active agent. These studies, however, do suggest that at least one metabolite, 5´-OH-thalidomide, has moderate antiangiogenic activity at high concentrations. Unfortunately, because of the lack of observed activity of 5´-OH-thalidomide in the human saphenous vein assay, it remains unclear whether there is species specificity for the activity of this metabolite.


Cancer Chemotherapy and Pharmacology | 1999

Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells.

Shannon C. Dixon; Erwin A. Kruger; Kenneth S. Bauer; William D. Figg

Abstract Thalidomide has been shown to have species- and metabolic-dependent antiangiogenic activity in vitro and in vivo, suggesting its potential in treating human angiogenesis-dependent pathologies such as solid tumors. Based on promising preclinical studies, thalidomide has entered phase II clinical trials for prostate, brain, breast cancer, and Kaposis sarcoma. However, the antiangiogenic mechanism of action is largely unresolved, as are its effects on tumor-associated gene expression, cytokine secretion, etc. We have investigated the effects of thalidomide on: 1) the secretion of prostate-specific antigen (PSA) in a human androgen-dependent prostate cell line; 2) growth and viability of human prostate cells; and 3) differential gene expression profiles of thalidomide-treated vs untreated human prostate cells. A human androgen-dependent prostate carcinoma cell line (LNCaP) and a human androgen-independent prostate carcinoma cell line (PC-3) were incubated with thalidomide 0.6, 6, or 60 μg/mL for 5–6 days. Secreted PSA from LNCaP cells was measured using a commercial enzyme-linked immunosorbant assay. Cell viability studies were conducted in both LNCaP and PC-3 cells using the same thalidomide concentrations. Furthermore, the differential gene expression of thalidomide-treated LNCaP cells was compared to that of untreated control cells using a commercially available human cancer cDNA expression array system. Thalidomide-treated LNCaP cells demonstrated increased PSA/cell levels at all concentrations tested compared to untreated control cells. Thalidomide demonstrated a cytostatic effect in LNCaP cells but had no appreciable effect on PC-3 cell viability compared to untreated control cells. Comparison of cDNA expression arrays hybridized with thalidomide-treated LNCaP cDNA probes suggests that thalidomide may up- or downregulate expression of angiogenesis-related genes, i.e., vitronectin, but these differential effects require further verification. Thalidomide over a range of doses has demonstrated nontoxic, cytostatic activity in LNCaP cells and significant upregulation of LNCaP cell PSA secretion in vitro. Furthermore, preliminary data from cDNA nucleic acid arrays of thalidomide-treated LNCaP cells suggest that thalidomide upregulates a potential angiogenic modulatory protein, the vitronectin precursor, which may eventually link thalidomides antiangiogenic activity with modulation of angiogenic vascular integrin pathways.


BioTechniques | 2002

Microarray gene expression profiling of angiogenesis inhibitors using the rat aortic ring assay

Theresa G. Zogakis; Nick G. Costouros; Erwin A. Kruger; S. Forbes; Mei He; M. Qian; Andrew L. Feldman; William D. Figg; H. R. Alexander; Edison T. Liu; Elise C. Kohn; Steven K. Libutti

The rat aortic ring assay has been previously described as a useful ex vivo model for analyzing the biological activity of various inhibitors of angiogenesis. Rat aortic rings are exposed to antiangiogenic agents for a five-day incubation period. Then, the degree of microvessel outgrowth from the rings is analyzed and quantified. In contrast to most in vitro angiogenesis assays, the rat aortic ring model provides a unique microenvironment to evaluate the interaction of various cell types and biological factors for their influence on angiogenesis. Microarray analysis is an accepted method for the evaluation of gene expression profiles and can be used to better understand changes in gene expression that occur when rat aortic rings are exposed to a particular biological agent. Here we describe a method of using microarray technology to evaluate the modulation of gene expression in angiogenesis using the rat aortic ring assay.


Clinical Cancer Research | 2001

A Randomized Phase II Trial of Thalidomide, an Angiogenesis Inhibitor, in Patients with Androgen-independent Prostate Cancer

William D. Figg; William L. Dahut; Paul H. Duray; Michael Hamilton; Anne Tompkins; Seth M. Steinberg; Elizabeth Jones; Ahalya Premkumar; W. Marston Linehan; Mary Kay Floeter; Clara C. Chen; Shannon C. Dixon; David R. Kohler; Erwin A. Kruger; Ed Gubish; James M. Pluda; Eddie Reed


Journal of Surgical Research | 2000

The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing.

Adam C. Berger; Andrew L. Feldman; Michael Gnant; Erwin A. Kruger; B.Kim Lee Sim; Stephen M. Hewitt; William D. Figg; H. Richard Alexander; Steven K. Libutti

Collaboration


Dive into the Erwin A. Kruger's collaboration.

Top Co-Authors

Avatar

William D. Figg

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Shannon C. Dixon

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Steven K. Libutti

Albert Einstein College of Medicine

View shared research outputs
Top Co-Authors

Avatar

Douglas K. Price

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Paul H. Duray

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Adam C. Berger

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Elise C. Kohn

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge